etherna

General Information

Company Name

etherna

Founded Year

2013

Location (Offices)

Belgium +2

Founders / Decision Makers

Number of Employees

116

Industries

Biotechnology, Health Care, Health and Wellness +1

Funding Stage

Series B

Social Media

etherna - Company Profile

Etherna is a biotechnology company based in Belgium, founded in 2013 and specializing in advancing RNA medicine. The company offers professional partnership to pharma and biotech companies with an interest in RNA therapeutics. Etherna's expertise lies in LNP formulation and RNA chemistry, supporting projects at all stages of development. Their proprietary platforms drive pipeline development and address manufacturing challenges for partners. Notably, Etherna recently secured a €39.00M Series B investment on August 23, 2022, with backing from a consortium of investors including Fund+, Grand Pharma, Novalis LifeSciences, Omega Funds, PMV, EQT Life Sciences, and Kenneth Chien. For more information, visit www.etherna.be and www.ethernamanufacturing.com.

Taxonomy: RNA technology, RNA therapeutics, pharma partnership, biotech partnership, pipeline development, manufacturing challenges, LNP formulation, RNA chemistry, Process Technology, nucleic acid-based medicines, mRNA production, drug product production, mRNA therapies, RNA manufacturing

Funding Rounds & Investors of etherna (5)

View All

Funding Stage	Amount	No. Investors	Investors	Date
Series B	€39.00M	7	EQT Life Sciences, Kenneth Chien	23 Aug 2022
Grant	$6.90M	1	European Commission	22 Mar 2021
Series B	€34.00M	2		16 Jun 2020
Grant	€1.00M	-		25 Sep 2017
Series A	€24.00M	-		14 Mar 2016